Demência com corpos de Lewy

Referências

Principais artigos

McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 4;89(1):88-100.Texto completo  Resumo

Expert Panel on Neurological Imaging; Moonis G, Subramaniam RM, Trofimova A, et al. ACR Appropriateness Criteria® dementia. J Am Coll Radiol. 2020 May;17(5s):S100-12.Texto completo  Resumo

Taylor JP, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020 Feb;19(2):157-69.Texto completo  Resumo

O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017 Feb;31(2):147-68. Resumo

Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504.Texto completo  Resumo

Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016 May 1;173(5):543-6.Texto completo  Resumo

Artigos de referência

1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 4;89(1):88-100.Texto completo  Resumo

2. Hemminghyth MS, Chwiszczuk LJ, Rongve A, et al. The cognitive profile of mild cognitive impairment due to dementia with Lewy bodies - an updated review. Front Aging Neurosci. 2020 Dec 23;12:597579.Texto completo  Resumo

3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th ed., text revision (DSM-5-TR). Washington, DC: American Psychiatric Publishing; 2022.

4. American Psychiatric Association. DSM-5-TR neurocognitive disorders supplement. Updated excerpts for delirium codes. Major and mild neurocognitive disorders. Oct 2022 [internet publication].Texto completo

5. GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022 Feb;7(2):e105-25.Texto completo  Resumo

6. Expert Panel on Neurological Imaging; Moonis G, Subramaniam RM, Trofimova A, et al. ACR Appropriateness Criteria® dementia. J Am Coll Radiol. 2020 May;17(5s):S100-12.Texto completo  Resumo

7. Ferman TJ, Smith GE, Kantarci K, et al. Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology. 2013 Dec 3;81(23):2032-8. Resumo

8. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing. 2005 Nov;34(6):561-6.Texto completo  Resumo

9. Podcasy JL, Epperson CN. Considering sex and gender in Alzheimer disease and other dementias. Dialogues Clin Neurosci. 2016 Dec;18(4):437-46.Texto completo  Resumo

10. Mouton A, Blanc F, Gros A, et al. Sex ratio in dementia with Lewy bodies balanced between Alzheimer's disease and Parkinson's disease dementia: a cross-sectional study. Alzheimers Res Ther. 2018 Sep 12;10(1):92.Texto completo  Resumo

11. Rampello L, Cerasa S, Alvano A, et al. Dementia with Lewy bodies: a review. Arch Gerontol Geriatr. 2004 Jul-Aug;39(1):1-14. Resumo

12. Bogaerts V, Engelborghs S, Kumar-Singh S, et al. A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain. 2007 Sep;130(Pt 9):2277-91.Texto completo  Resumo

13. Ohara K, Takauchi S, Kokai M, et al. Familial dementia with Lewy bodies (DLB). Clin Neuropathol. 1999 Sep-Oct;18(5):232-9. Resumo

14. Rosenberg CK, Cummings TJ, Saunders AM, et al. Dementia with Lewy bodies and Alzheimer's disease. Acta Neuropathol. 2001 Dec;102(6):621-6. Resumo

15. Bras J, Guerreiro R, Darwent L, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Hum Mol Genet. 2014 Dec 1;23(23):6139-46Texto completo  Resumo

16. Samuel W, Galasko D, Masliah E, et al. Neocortical Lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease. J Neuropathol Exp Neurol. 1996 Jan;55(1):44-52. Resumo

17. Weisman D, Cho M, Taylor C, et al. In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology. 2007 Jul 24;69(4):356-9. Resumo

18. Armstrong MJ. Advances in dementia with Lewy bodies. Ther Adv Neurol Disord. 2021 Nov 23;14:17562864211057666.Texto completo  Resumo

19. Galvin JE. Improving the clinical detection of lewy body dementia with the lewy body composite risk score. Alzheimers Dement (Amst). 2015 Sep 1;1(3):316-24.Texto completo  Resumo

20. Ryu HJ, Kim M, Moon Y, et al. Validation of the Korean version of the Lewy Body Composite Risk Score (K-LBCRS). J Alzheimers Dis. 2017;55(4):1395-401. Resumo

21. Ferman TJ, Smith GE, Boeve BF, et al. DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging. Neurology. 2004 Jan 27;62(2):181-7. Resumo

22. Chan PC, Lee HH, Hong CT, et al. REM sleep behavior disorder (RBD) in dementia with Lewy bodies (DLB). Behav Neurol. 2018 Jun 19;2018:9421098.Texto completo  Resumo

23. Roguski A, Rayment D, Whone AL, et al. A neurologist's guide to REM sleep behavior disorder. Front Neurol. 2020 Jul 8;11:610.Texto completo  Resumo

24. Fahn S, Elton RL; UPDRS program members. Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, et al, eds. Recent developments in Parkinson’s disease. Vol 2. Florham Park, NJ: Macmillan Healthcare; 1987:153-63.

25. Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994 Dec;44(12):2308-14. Resumo

26. Zupancic M, Mahajan A, Handa K. Dementia with Lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord. 2011;13(5):PCC.11r01190.Texto completo  Resumo

27. Quigley H, Colloby SJ, O'Brien JT. PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry. 2011 Oct;26(10):991-9. Resumo

28. Bonanni L, Franciotti R, Nobili F, et al. EEG markers of dementia with Lewy bodies: a multicenter cohort study. J Alzheimers Dis. 2016 Oct 18;54(4):1649-57. Resumo

29. Janvin C, Larsen J, Salmon D, et al. Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with Lewy bodies and Alzheimer's disease. Mov Disord. 2006 Mar;21(3):337-42. Resumo

30. Tiraboschi P, Salmon D, Hansen L, et al. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia? 2006 Mar;129(Pt 3):729-35.Texto completo  Resumo

31. Burn DJ. Cortical Lewy body disease and Parkinson's disease dementia. Curr Opin Neurol. 2006 Dec;19(6):572-9. Resumo

32. Taylor JP, McKeith IG, Burn DJ, et al. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020 Feb;19(2):157-69.Texto completo  Resumo

33. National Institute for Health and Care Excellence. Dementia: assessment, management and support for people living with dementia and their carers. Jun 2018 [internet publication].Texto completo

34. Salmon DP, Galasko D, Hansen LA, et al. Neuropsychological deficits associated with diffuse Lewy body disease. Brain Cogn. 1996 Jul;31(2):148-65. Resumo

35. Watson R, Blamire AM, O'Brien JT. Magnetic resonance imaging in Lewy body dementias. Dement Geriatr Cogn Disord. 2009;28(6):493-506.Texto completo  Resumo

36. Stinton C, McKeith I, Taylor JP, et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis. Am J Psychiatry. 2015 Aug 1;172(8):731-42.Texto completo  Resumo

37. Wang HF, Yu JT, Tang SW, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):135-43.Texto completo  Resumo

38. Chiong W, Tsou AY, Simmons Z, et al. Ethical considerations in dementia diagnosis and care: AAN position statement. Neurology. 2021 Jul 13;97(2):80-9.Texto completo  Resumo

39. Taylor LP, Besbris JM, Graf WD, et al. Clinical guidance in neuropalliative care: an AAN position statement. Neurology. 2022 Mar 8;98(10):409-16.Texto completo  Resumo

40. Walsh SC, Murphy E, Devane D, et al. Palliative care interventions in advanced dementia. Cochrane Database Syst Rev. 2021 Sep 28;(9):CD011513.Texto completo  Resumo

41. Iverson DJ, Gronseth GS, Reger MA, et al. Practice parameter update: evaluation and management of driving risk in dementia: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2010 Apr 20;74(16):1316-24.Texto completo  Resumo

42. Howell M, Avidan AY, Foldvary-Schaefer N, et al. Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2023 Apr 1;19(4):759-68.Texto completo  Resumo

43. Aarsland D, Brønnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry. 2007 Jan;78(1):36-42.Texto completo  Resumo

44. Hepburn K, Lewis M, Tornatore J, et al. The Savvy Caregiver program: the demonstrated effectiveness of a transportable dementia caregiver psychoeducation program. J Gerontol Nurs. 2007 Mar;33(3):30-6. Resumo

45. Griffiths PC, Kovaleva M, Higgins M, et al. Tele-Savvy: an online program for dementia caregivers. Am J Alzheimers Dis Other Demen. 2018 Aug;33(5):269-76.Texto completo  Resumo

46. Kally Z, Cote SD, Gonzalez J, et al. The Savvy Caregiver Program: impact of an evidence-based intervention on the well-being of ethnically diverse caregivers. J Gerontol Soc Work. 2014;57(6-7):681-93. Resumo

47. Connors MH, Quinto L, McKeith I, et al. Non-pharmacological interventions for Lewy body dementia: a systematic review. Psychol Med. 2018 Aug;48(11):1749-58.Texto completo  Resumo

48. Orgeta V, Leung P, Del-Pino-Casado R, et al. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment. Cochrane Database Syst Rev. 2022 Apr 25;(4):CD009125.Texto completo  Resumo

49. Bahar-Fuchs A, Martyr A, Goh AM, et al. Cognitive training for people with mild to moderate dementia. Cochrane Database Syst Rev. 2019 Mar 25;(3):CD013069.Texto completo  Resumo

50. Abraha I, Rimland JM, Trotta FM, et al. Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series. BMJ Open. 2017 Mar 16;7(3):e012759. [Erratum in: BMJ Open. 2017 Jul 17;7(7):e012759corr1.]Texto completo  Resumo

51. van der Steen JT, Smaling HJ, van der Wouden JC, et al. Music-based therapeutic interventions for people with dementia. Cochrane Database Syst Rev. 2018 Jul 23;(7):CD003477.Texto completo  Resumo

52. Leng M, Zhao Y, Wang Z. Comparative efficacy of non-pharmacological interventions on agitation in people with dementia: a systematic review and Bayesian network meta-analysis. Int J Nurs Stud. 2020 Feb;102:103489. Resumo

53. O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol. 2017 Feb;31(2):147-68. Resumo

54. Rolinski M, Fox C, Maidment I, et al. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504.Texto completo  Resumo

55. McKeith IG, Mosimann UP. Dementia with Lewy bodies and Parkinson's disease. Parkinsonism Relat Disord. 2004 May;10(suppl 1):S15-8. Resumo

56. Sorbi S, Hort J, Erkinjuntti T, et al. EFNS-ENS guidelines on the diagnosis and management of disorders associated with dementia. Eur J Neurol. 2012 Sep;19(9):1159-79.Texto completo  Resumo

57. McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;(3):CD003154.Texto completo  Resumo

58. Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016 May 1;173(5):543-6.Texto completo  Resumo

59. Yunusa I, Alsumali A, Garba AE, et al. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open. 2019 Mar 1;2(3):e190828.Texto completo  Resumo

60. Tariot PN, Cummings JL, Soto-Martin ME, et al. Trial of pimavanserin in dementia-related psychosis. N Engl J Med. 2021 Jul 22;385(4):309-19.Texto completo  Resumo

61. Boeve BF, Silber MH, Parisi JE, et al. REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol. 2004 Sep;17(3):146-57.Texto completo  Resumo

62. Watt JA, Goodarzi Z, Veroniki AA, et al. Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis. BMJ. 2021 Mar 24;372:n532.Texto completo  Resumo

63. Emre M, Tsolaki M, Bonuccelli U, et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Oct;9(10):969-77. Resumo

64. Kurtz AL, Kaufer DI. Dementia in Parkinson's disease. Curr Treat Options Neurol. 2011 Jun;13(3):242-54. Resumo

65. Substance Abuse and Mental Health Services Administration. Emergency department visits involving nonmedical use of the anti-anxiety medication alprazolam. The CBHSQ Report. Rockville, MD: Substance Abuse and Mental Health Services Administration (US); 2014.Texto completo

66. Desai AK, Grossberg GT. Recognition and management of behavioral disturbances in dementia. Prim Care Companion J Clin Psychiatry. 2001 Jun;3(3):93-109.Texto completo  Resumo

67. Molloy S, McKeith IG, O'Brien JT, et al. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005 Sep;76(9):1200-3.Texto completo  Resumo

68. Lucetti C, Logi C, Del Dotto P, et al. Levodopa response in dementia with Lewy bodies: a 1-year follow-up study. Parkinsonism Relat Disord. 2010 Sep;16(8):522-6. Resumo

69. Davies N, Barrado-Martín Y, Vickerstaff V, et al. Enteral tube feeding for people with severe dementia. Cochrane Database Syst Rev. 2021 Aug 13;(8):CD013503.Texto completo  Resumo

70. Stefani A, Santamaria J, Iranzo A, et al. Nelotanserin as symptomatic treatment for rapid eye movement sleep behavior disorder: a double-blind randomized study using video analysis in patients with dementia with Lewy bodies or Parkinson's disease dementia. Sleep Med. 2021 May;81:180-7.Texto completo  Resumo

71. Lang FM, Kwon DY, Aarsland D, et al. An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB). Alzheimers Dement (NY). 2021;7(1):e12171.Texto completo  Resumo

72. Biglan K, Munsie L, Svensson KA, et al. Safety and efficacy of mevidalen in Lewy body dementia: a phase 2, randomized, placebo-controlled trial. Mov Disord. 2022 Mar;37(3):513-24.Texto completo  Resumo

73. ClinicalTrials.gov. Cognitive effects of oral p38 alpha kinase inhibitor neflamapimod in dementia with Lewy bodies (AscenD-LB). NCT04001517. 2 November 2021 [internet publication].Texto completo

74. Cummings JL, Lyketsos CG, Peskind ER, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial. JAMA. 2015 Sep 22-29;314(12):1242-54.Texto completo  Resumo

75. Magierski R, Sobow T, Schwertner E, et al. Pharmacotherapy of behavioral and psychological symptoms of dementia: state of the art and future progress. Front Pharmacol. 2020 Jul 31;11:1168.Texto completo  Resumo

76. ClinicalTrials.gov. The effect of cannabis on dementia related agitation and aggression. NCT03328676. 8 March 2022 [internet publication].Texto completo

77. Alagiakrishnan K, Bhanji RA, Kurian M. Evaluation and management of oropharyngeal dysphagia in different types of dementia: a systematic review. Arch Gerontol Geriatr. 2013 Jan-Feb;56(1):1-9. Resumo

78. British Geriatrics Society. Driving with dementia or mild cognitive impairment: consensus guidelines for clinicians. 10 January 2019 [internet publication].Texto completo

O uso deste conteúdo está sujeito ao nosso aviso legal